Aura Biosciences, Inc. (AURA)
NASDAQ: AURA · Real-Time Price · USD
7.10
+0.22 (3.20%)
At close: Jun 30, 2026, 4:00 PM EDT
7.10
0.00 (0.00%)
After-hours: Jun 30, 2026, 4:38 PM EDT
Aura Biosciences Employees
Aura Biosciences had 113 employees as of December 31, 2025. The number of employees increased by 4 or 3.67% compared to the previous year.
Employees
113
Change (1Y)
4
Growth (1Y)
3.67%
Revenue / Employee
n/a
Profits / Employee
-$994,628
Market Cap
783.13M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 113 | 4 | 3.67% | 113 | 0 |
| Dec 31, 2024 | 109 | 20 | 22.47% | 106 | 3 |
| Dec 31, 2023 | 89 | 17 | 23.61% | 88 | 1 |
| Dec 31, 2022 | 72 | 20 | 38.46% | 70 | 2 |
| Dec 31, 2021 | 52 | - | - | 52 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Omeros | 175 |
| Rigel Pharmaceuticals | 174 |
| Allogene Therapeutics | 152 |
| Inventiva | 77 |
| SpyGlass Pharma | 68 |
| Oculis Holding AG | 60 |
| Candel Therapeutics | 55 |
| Climb Bio | 29 |
AURA News
- 1 day ago - Aura Biosciences Proxy statement: Proxy filing - Filings
- 13 days ago - Aura Biosciences Proxy statement: Proxy filing - Filings
- 13 days ago - Auranova and Kenorland Announce Large Intrusion-Related Gold Discovery at the South Uchi Project, Ontario - Newsfile Corp
- 19 days ago - Aura Biosciences Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Aura Biosciences completes enrollment in belzupacap sarotalocan trial - TheFly
- 4 weeks ago - Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma - GlobeNewsWire
- 4 weeks ago - Aura Biosciences Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 6 weeks ago - Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire